Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 8.9%

Gyre Therapeutics, Inc. (NASDAQ:GYRE) dropped 8.9% during trading on Tuesday . The stock traded as low as $12.55 and last traded at $12.55. Approximately 15,582 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 72,680 shares. The stock had previously closed at $13.77.

Gyre Therapeutics Trading Down 4.4 %

The business’s fifty day moving average is $12.66 and its 200 day moving average is $14.37.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings results on Tuesday, August 13th. The company reported $0.01 EPS for the quarter. The firm had revenue of $25.23 million for the quarter. As a group, analysts forecast that Gyre Therapeutics, Inc. will post -0.45 EPS for the current year.

Insiders Place Their Bets

In other news, Director Nassim Usman sold 3,452 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $12.00, for a total value of $41,424.00. Following the completion of the transaction, the director now owns 1,636 shares in the company, valued at $19,632. The sale was disclosed in a document filed with the SEC, which is available at this link. 2.92% of the stock is owned by company insiders.

Institutional Trading of Gyre Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC acquired a new position in shares of Gyre Therapeutics during the 2nd quarter worth approximately $166,000. WINTON GROUP Ltd purchased a new position in Gyre Therapeutics during the second quarter worth $220,000. Rhumbline Advisers acquired a new position in shares of Gyre Therapeutics in the second quarter worth $123,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Gyre Therapeutics in the second quarter valued at $218,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.